Heeding the pleas of the US government and biopharmaceutical industry, the full US Court of Appeals for the Federal Circuit ruled that Ben Venue Laboratories Inc.'s contract manufacturing of The Medicines Co.'s anticoagulant Angiomax (bivalirudin) was not a commercial sale and thus did not invalidate the company's patents.
The July 11 decision in The Medicines Company v. Hospira clarifies the application of the on-sale bar provision...





